One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors

Authors:
  • NYNaoto Yokota
    Naoto Yokota
  • YIYoshinari Ichiki
    Yoshinari Ichiki
  • TATakao Ayabe
    Takao Ayabe
  • TETakuma Etoh
    Takuma Etoh
  • NTNoboru Tamaki
    Noboru Tamaki
  • JKJohji Kato
    Johji Kato
  • TETanenao Eto
    Tanenao Eto
  • KKKazuo Kitamura
    Kazuo Kitamura

Abstract
The long-term antihypertensive efficacy and safety of losartan/hydrochlorothiazide (HCTZ) combinations have not been appropriately evaluated in Japan. In this study, treated hypertensive patients taking angiotensin-receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) regimens not at blood pressure (BP) goals proposed by the Japanese Society of Hypertension (JSH) were switched to losartan/HCTZ combinations and followed for 1 year. Data analysis included 244 patients aged 64.5+/-10.7 years, 56% male, 27% with diabetes mellitus and 36% with dyslipidemia. Pre-switching BP 157+/-16/88+/-10 mm Hg promptly decreased and maintained a steady state, reaching 132+/-15/77+/-9 mm Hg (P/=7.0 mg dl(-1)). Losartan/HCTZ combinations showed strong and steady hypotensive abilities and acceptable safety and tolerability in patients currently not at BP goals with regimens including ARBs or ACEIs in Japan.

This publication has 19 references indexed in Scilit: